ADCs Are Reshaping Cancer Treatment — Explore The Need-To-Knows Of Their Manufacture

Antibody-drug conjugates (ADCs) continue to generate excitement across the biopharmaceutical industry, offering the potential to deliver highly targeted therapies for cancer and other difficult-to-treat diseases. As innovation expands beyond traditional ADCs to include next-generation bioconjugates such as antibody-oligonucleotide conjugates (AOCs), developers are pushing the boundaries of molecular design, conjugation technologies, and payload delivery. However, these advances are also introducing new manufacturing and development challenges.

In a recent discussion, experts from Abzena and Frost & Sullivan explored the trends reshaping the ADC landscape and the implications for sponsors seeking development and manufacturing partners. From the growing importance of advanced analytical capabilities and end-to-end integration to evolving expectations around regulatory support, technology transfer, and lifecycle accountability, the conversation highlighted how CDMO selection criteria are changing. Download the full article to read their insights, which offer a valuable look at the technologies, partnerships, and strategies that will help bring the next generation of bioconjugate therapies to patients faster and with less risk.